$NVLX According to the American cancer Society, in the US

New Post Public Reply Private Reply Replies (0) Message Board
Tandrel
$NVLX According to the American cancer Society, in the US alone, approximately 45,000 new cases of pancreatic cancer are expected to be diagnosed this year and about 38,000 people are predicted to die from the disease; it is the leading cause of cancer deaths in the US and worldwide. Often pancreatic cancer is not diagnosed until it has reached an advanced stage. By this time, the cancer cannot be removed surgically, is often resistant to radiation therapy or chemotherapy, and has spread (metastasized) to other organs in the body. Because of this, the average survival of patients with advanced, inoperable pancreatic cancer is given in terms of weeks or months, not years.Nuvilex’s pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and widely used anticancer drug ifosfamide.In a Phase I/II open-label, prospective, single-arm clinical trial, the live-cell encapsulation/ifosfamide combination was used to treat patients with advanced, inoperable pancreatic cancer. Fifty-one patients were originally “screened” for the trial; of these, 17 were enrolled in the study. Other patients were excluded from enrollment for therapy because of previous chemotherapy, previous pancreatic surgery, poor overall health, unwillingness to participate, or death prior to the start of the trial. Of the 17 patients initially enrolled in the study, 14 were ultimately treated. Results obtained in the clinical trial were compared with historical data for gemcitabine and included: median survival time of 44 weeks (after diagnosis) with the cell encapsulation/ifosfamide treatment as compared to 28 weeks with gemcitabine; doubling of the one-year survival rate – 36% with our treatment vs. 18% with gemcitabine; tumor volume was reduced 25-50% in 4 of the 14 treated patients and remained stable in the remaining patients; no serious drug-related side effects with the encapsulated cell/ifosfamide treatment whereas serious and very serious side effects were reported with gemcitabine; the lack of serious side effects using our treatment is probably related to the use of “lower than normal” doses of ifosfamide; limited side effects and reduced cancer pain intensity led to a generally increased ‘quality of life” for the majority of patients. In a “worst case” scenario, some clinical benefit was seen in 50% of patients and in a “best case” scenario, this number increased to 71%; none of the patients who experienced a clinical benefit required and increase in their pain medication.

PharmaCyte Biotech Inc. (PMCB) Stock Research Links

PMCB Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dickinson Brands Celebrates Witch Hazel Legacy with Event

Updated Category News Views 14

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Continue Reading
Art Print Paper: Finding the Perfect Match for Masterpieces

Updated Category News Views 8

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...

Continue Reading
Florida Cancer Center Expands Expertise with New Oncologist

Updated Category News Views 8

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Continue Reading
Sarah Weede: A Force in Veterans Services Leadership

Updated Category News Views 5

Saluting a Veteran's Advocate Amidst a world obsessed with bottom lines and market swings, it’s refreshing to spotlight someone like Sarah R. Weede. She's not about the Wall Street grind but you better believe her drive and dedication rival any big-shot CEO. Leadership in Veterans Services Sarah Weede's story starts with substantial roots planted in serving those who...

Continue Reading
D2L Ventures into Vietnam with Van Lang Alliance

Updated Category News Views 6

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Continue Reading
Navigating the Nitty-Gritty of Cabin Rental Management

Updated Category News Views 4

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Continue Reading
TomoIQ Unveils Money Finder at Money20/20 Event

Updated Category News Views 11

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

Continue Reading
Firmable's Tech Intelligence: New Edge in B2B Sales

Updated Category News Views 5

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

Continue Reading
Taiwan Excellence Sparks Smart Automotive Innovation at SEMA

Updated Category News Views 1

Taiwan's making waves, folks, and it's not your everyday splash in the automotive pool. At SEMA 2026, Taiwan Excellence Pavilion is the place to be with its array of intelligent automotive solutions. This ain't just your run-of-the-mill car show gimmickry—it's the future rolling in real-time. Driving Innovation: From Components to Smart Systems The name of the game is...

Continue Reading
Ford Foundation Welcomes Gender Justice Leader Fatima Goss Graves

Updated Category News Views 5

A Fresh Addition to Ford's Trustees Fatima Goss Graves steps into big shoes at the Ford Foundation as she gets appointed to its Board of Trustees. No small potatoes, this move suggests the Foundation's commitment to driving significant gender justice and advocacy. Add her name next to serious change-makers, folks, because Ms. Goss Graves is a heavyweight in the nonprofit...

Continue Reading

Top 5 Most Recently Viewed Articles

AbbVie Inc: Key Trading Signals Boost Stock Performance

Updated Category News Views 155

Recent Trading Momentum for AbbVie Inc AbbVie Inc (NYSE: ABBV) has caught the attention of traders with significant fluctuations in stock prices, predominantly influenced by notable trading signals. Recently, the stock experienced an impressive Power Inflow alert, which traders regard as a critical bullish indicator. This alert hinges on valuable order flow analytics that...

Continue Reading
Ormat Technologies' 2024 Financial Performance Review

Updated Category News Views 352

Ormat Technologies' Strong Performance in 2024 Ormat Technologies, Inc. (NYSE: ORA), a prominent player in the renewable energy sector, has recently released its financial performance report for the fourth quarter and full year of 2024. This announcement marks another year of substantial growth, driven by a robust strategic approach that enhances its operational...

Continue Reading
Exploring State Street's Financial Metrics and Market Trends

Updated Category News Views 187

Current Stock Performance of State Street Currently, State Street Inc. (NYSE: STT) has a share price of $112.20, experiencing a minor decline of 0.21%. Despite this slight drop, it’s encouraging to note that the stock has seen an increase of 0.87% over the past month and a significant growth of 29.33% in the past year. This variability poses an intriguing question for...

Continue Reading
Fortrea Enhances Board with Financial Expert Erin L. Russell

Updated Category News Views 368

Fortrea Welcomes Erin L. Russell to Its Board of Directors In an exciting new development, Fortrea has recently appointed Erin L. Russell to its Board of Directors, signaling a robust commitment to enhancing its strategic direction and governance. This decision comes as part of a collaboration with Starboard Value LP, an investment firm that holds a significant stake in...

Continue Reading
Analyzing the Current Market Sentiment Towards Laureate Education

Updated Category News Views 168

Understanding Laureate Education's Market Position Laureate Education Inc (NYSE: LAUR) has recently shown a decline in its short percent of float, which has dropped 7.46% since the last report. Currently, the company indicates that it has 2.44 million shares sold short. This accounts for about 2.11% of all shares available for trading. Given its current trading volume, it...

Continue Reading